JNCEUnknown
Jounce Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Jounce Therapeutics, Inc. (JNCE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are JNCE insiders buying or selling?
Jounce Therapeutics, Inc. insiders reported 2 open-market buys ($100.9K) and 40 sells ($41.1M) across 42 Form 4 filings — a net selling position of $41.0M.
Source: SEC EDGAR Form 4
Key Statistics (as of Apr 6, 2023)
Total Form 4 filings
42
SEC EDGAR
Insider filers
9
Insider buys (2)
$100.9K
Insider sells (40)
$41.1M
Insider sentiment
Net sellingNet insider flow of $41.0M in net selling.
Recent JNCE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 6, 2023 | Richard /Ca/ Murray | Director | Sale | 39.2K | $1.85 | $72.6K |
| Mar 15, 2023 | Kevin C Tang | 10% Owner | Purchase | 86.0K | $1.00 | $86.0K |
| Jan 12, 2023 | Elizabeth Trehu | Chief Medical Officer | Sale | 9.3K | $1.11 | $10.3K |
| Jan 12, 2023 | Richard /Ca/ Murray | CEO and President | Sale | 45.1K | $1.11 | $50.1K |
| Jan 12, 2023 | Kimberlee C Drapkin | CFO and Treasurer | Sale | 14.1K | $1.11 | $15.7K |
| Jan 12, 2023 | Hugh M Cole | Chief Operating Officer | Sale | 16.6K | $1.11 | $18.5K |
| Jan 12, 2022 | Elizabeth Trehu | Chief Medical Officer | Sale | 8.4K | $6.88 | $57.7K |
| Jan 12, 2022 | Richard /Ca/ Murray | CEO and President | Sale | 37.3K | $6.88 | $256.7K |
| Nov 17, 2021 | Kevin P Starr | 10% Owner | Sale | 1.9M | $8.38 | $15.9M |
| May 27, 2021 | Kevin P Starr | 10% Owner | Sale | 552.5K | $8.00 | $4.4M |
| Apr 17, 2021 | John Duncan Higgons | Director | Sale | 200 | $10.00 | $2.0K |
| Apr 1, 2021 | Elizabeth Trehu | Chief Medical Officer | Sale | 13.5K | $10.09 | $136.2K |
| Mar 18, 2021 | John Duncan Higgons | Director | Sale | 200 | $12.80 | $2.6K |
| Mar 3, 2021 | Kevin P Starr | 10% Owner | Sale | 1.4M | $11.75 | $17.0M |
| Feb 19, 2021 | John Duncan Higgons | Director | Sale | 200 | $11.78 | $2.4K |
| Jan 25, 2021 | Richard /Ca/ Murray | CEO and President | Sale | 33.5K | $12.06 | $404.2K |
| Jan 25, 2021 | Hugh M Cole | Chief Business Officer | Sale | 18.0K | $11.95 | $215.1K |
| Jan 22, 2021 | Elizabeth Trehu | Chief Medical Officer | Sale | 6.5K | $12.01 | $78.1K |
| Jan 22, 2021 | John Duncan Higgons | Director | Sale | 1.7K | $11.90 | $20.2K |
| Jan 22, 2021 | Kimberlee C Drapkin | CFO and Treasurer | Sale | 30.0K | $11.36 | $340.8K |
| Jan 21, 2021 | Richard /Ca/ Murray | CEO and President | Sale | 86.5K | $9.69 | $838.2K |
| Jan 11, 2021 | Elizabeth Trehu | Chief Medical Officer | Sale | 5.3K | $6.89 | $36.5K |
| Jan 11, 2021 | Richard /Ca/ Murray | CEO and President | Sale | 22.0K | $6.89 | $151.5K |
| Jan 11, 2021 | Kimberlee C Drapkin | CFO and Treasurer | Sale | 5.8K | $6.89 | $40.1K |
| Jan 11, 2021 | Hugh M Cole | Chief Business Officer | Sale | 6.2K | $6.89 | $42.8K |
Showing the 25 most recent of 42 Form 4 filings for Jounce Therapeutics, Inc..
Most active JNCE insiders
- Elizabeth Trehu8 filings
- Richard /Ca/ Murray8 filings
- Hugh M Cole7 filings
- Kimberlee C Drapkin7 filings
- John Duncan Higgons5 filings
Ask anything about JNCE insider activity
Use Trabud's AI agent to query Jounce Therapeutics, Inc.'s Form 4 history in plain English — "Show me JNCE CEO purchases this year" or compare it against any other ticker.
Open the AI agentJNCE insider trading FAQ
Are Jounce Therapeutics, Inc. insiders buying or selling?
Across 42 SEC Form 4 filings, Jounce Therapeutics, Inc. (JNCE) insiders reported 2 open-market purchases totaling $100.9K and 40 sales totaling $41.1M. That is a net selling position of $41.0M.
How many insiders trade JNCE stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Jounce Therapeutics, Inc.. The most recent filing was accepted on Apr 6, 2023.
Where does Trabud get JNCE insider trading data?
All JNCE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.